Densitometric simultaneous assessment of teneligliptin hydrobromide and pioglitazone hydrochloride in combined tablet

Abstract

Abstract A highly effective high‐performance thin‐layer chromatographic methodology has been developed and validated for the concurrent measurement of teneligliptin hydrobromide hydrate and pioglitazone hydrochloride in tablet offering excellent sensitivity, precision, accuracy, and robustness. The methodology involved using aluminum plates layered with silica gel 60F 254 were used, and the solvent system consisted of a mixture of chloroform, methanol, and ammonia (8:1:0.5 v/v/v). The analysis involved scanning of the plate at a wavelength of 229 nm and analyzing the resulting densitograms. The linear correlation was established over a range of concentrations 250–3000 ng/band for teneligliptin hydrobromide hydrate and 187.5–2250 ng/band for pioglitazone hydrochloride. The method displayed detection limits of 21.29 ng/band for teneligliptin hydrobromide hydrate and 25.97 ng/band for pioglitazone hydrochloride. The quantification limits were 64.52 ng/band for teneligliptin hydrobromide hydrate and 78.71 ng/band for pioglitazone hydrochloride. The results of precision parameters showed that the % relative standard deviation of peak area was consistently below 2%, indicating high precision. The accuracy of the method was demonstrated to be between 96% and 103%. Proposed method was found to be superior and capable of overcoming the shortcomings of previously reported methods for the assessment of both the drugs.